chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Gas, dyspepsia, pain in chest and back, weakness, general malaise since getting vaccinations.
My hearing in my left ear has deteriorated substantially over the past 6 months.  All 3 vaccine doses were given in my left arm.
Client reported dizziness and was in bed x12 days and knees were "shaking"
Symptoms like MS Lack of awake/awareness/lucidity Extreme fatigue, sweats, blurred vision
Pt had some nausea. Had clinically evaluation and blood screen. No tx. Pt had sx after we discovered that the 3rd dose of HPV was given too early. First dose was on 2/12/08, 2nd dose was on 4/8/08, and the most current dose was 6/10/08.
on 5aug94 recvd 2nd dose & w/in 20 min c/o HA;after 3rd dose felt drowsy;
This spontaneous report was received from a registered nurse via medical assistant and refers to a 16-month-old female patient. The patient's pertinent medical history, concurrent conditions, concomitant medications, past drugs and drug allergies were not reported. On 19-SEP-2017, the patient was vaccinated with improperly stored M-M-R II (lot # M034387; expiry date: 19-JUL-2018) (dosing details were not provided) for prophylaxis. Temperature excursion details of the vaccine were not provided. This is one of the several reports received from the same source. Sender's Comments: US-009507513-1709USA008861: US-009507513-1710USA013424: US-009507513-1710USA013470: US-009507513-1710USA013465: US-009507513-1710USA013440: US-009507513-1710USA013468: US-009507513-1710USA013442: US-009507513-1710USA013445: US-009507513-1710USA013460: US-009507513-1710USA013463: US-009507513-1710USA013464: US-009507513-1710USA013438: US-009507513-1710USA013439: US-009507513-1710USA013450: US-009507513-1710USA013430: US-009507513-1710USA013469: US-009507513-1710USA013467: US-009507513-1710USA013435: US-009507513-1710USA013434: US-009507513-1710USA013432: US-009507513-1710USA013428: US-009507513-1710USA013437: US-009507513-1710USA013441: US-009507513-1710USA013443: US-009507513-1710USA013444: US-009507513-1710USA013446: US-009507513-1710USA013447: US-009507513-1710USA013448: US-009507513-1710USA013436: US-009507513-1710USA013449: US-009507513-1710USA013451: US-009507513-1710USA013452: US-009507513-1710USA013454: US-009507513-1710USA013455: US-009507513-1710USA013456: US-009507513-1710USA013457: US-009507513-1710USA013458: US-009507513-1710USA013459: US-009507513-1710USA013461: US-009507513-1710USA013462: US-009507513-1710USA013466: US-009507513-1710USA013427: US-009507513-1710USA013471: US-009507513-1710USA013472: US-009507513-1710USA013473: US-009507513-1710USA013474: US-009507513-1710USA013475: US-009507513-1710USA013476: US-009507513-1710USA013425: US-009507513-1710USA013433: US-009507513-1710USA013423: US-009507513-1710USA013040: US-009507513-1710USA013426: US-009507513-1710USA013429: US-009507513-1710USA013431: US-009507513-1709USA008666: Original Case: 1709USA008666: US-009507513-1710USA014650: Original Case: 1710USA014649: US-009507513-1710USA014651: Original Case: 1710USA014649: US-009507513-1710USA014649: Original Case: 1710USA014649.
Delirium - several hours unaccounted for, severe diarrhea, chill sweats, fever, woke up the following day with multiple facial bruising including massive black eye - cannot explain how it occurred
administered the liquid portion of the DTAP IPV vaccine forgot to mix in the powder (ActHIB) from Pentacel/No AE; Initial information regarding an unsolicited valid non-serious case was received from a other health professional via Agency (Reference number- 00515066) and transmitted to Sanofi on 11-Mar-2021.  This case involves a 6 months old female patient who administered with the liquid portion of the DTAP IPV vaccine forgot to mix in the powder (Act-Hib) from DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE [PENTACEL].  Medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included PNEUMOCOCCAL VACCINE CONJ 7V (CRM197) (PREVNAR); INFLUENZA VACCINE INACT SPLIT 4V (FLUZONE QUADRIVALENT); and ROTAVIRUS VACCINE LIVE REASSORT ORAL 5V (ROTATEQ) for Immunisation.  On 11-Mar-2021, the patient received a third 0.5 mL dose of suspect DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE (lot UJ413AA, Expiry date- 09-Oct-2021) via intramuscular route in the left thigh for prophylactic vaccination.  It was a case of an actual medication error due to Inappropriate reconstitution technique (latency same day).  Nurse clarifies that she is calling regarding Pentacel, not Quadracel. She asks how to administer the remaining powdered ActHIB portion of the Pentacel. She asks what diluent should be used. Did the issue occur before or after the mixing of the two components? Before If the issue occurred before the mixing, did the problem concern the powder vial or the diluent vial? Before, they forgot to mix in the powder (ActHIB) into the (Ipol/Daptacel) diluent.  It was not reported if the patient experienced any adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.  There will be no information available on the batch number for this case.
Information has been received from a registered nurse with no allergies or medical history who on 26-JUL-2004 and on 31-JAN-2005 was vaccinated with the first and second doses respectively of VAQTA (manufacturer unknown). There was no concomitant medication. On approximately 27-AUG-2008, the patient had a titer drawn for VAQTA that was negative. The patient sought medical attention at an office visit. A product quality complaint was not involved. Additional information has been requested.
Information has been received from a registered nurse concerning a 9 weeks old female with no pertinent medical history and drug reactions/allergies who on 28-NOV-2007 was vaccinated po with a "first dose of series" of Rotateq (lot number: 657977/1195U). Concomitant therapy (that day) on 28-NOV-2007 included Prevnar, Pediarix and Pedvax HIB. No other medications were noted. On 04-DEc-2007 the patient experienced diarrhea for 10 days. On 14-DEC-2007 unspecified medical attention was sought, the patient was seen in the office. The patient continued with 6 loose stools per day. The patient's formula was switched from enfamil to similac and back to enfamil supplementing the nursing. Some blood in stool the night (13-DEC-2007) before was noted. The outcome was reported as not recovered. There were no lab diagnostic studies performed. It was unknown if the patient will receive the next dose of Rotateq. No additional information was provided at this time. There was no product quality complaint. Upon internal review, blood in stool is considered to be an other medical event. Additional information has been requested.
This spontaneous report as received from a physician via a field representative refers to a 4 year old patient of unknown gender. On 08-OCT-2014 the patient was vaccinated with a dose of VARIVAX lot # K003420, exp. date unspecified, dose/frequency: 1 shot, therapy route: injection in the right thigh for vaccine. Patient received "ITV" at the same time. On 09-OCT-2014, the patient developed a varicella-like blister at injection site after receiving VARIVAX. No treatment was given for event. The outcome of the event was unknown. The causal relationship was not reported. Additional information has been requested.
Closed fracture of multiple ribs of right side. ED visit to hospital admission. This visit was within 6 weeks of receiving the COVID vaccine.
Fever, chills, fatigue, body aches, joint and muscle pain, nausea.  Symptoms began around 7pm 1/22 Fri. and are still happening as of 11:30 am Sunday 1/24.
Low estrogen; can't concentrate; can't focus; can't sleep; depressed; has anxiety; This is a spontaneous report from a contactable consumer (patient). This consumer reported same events under same suspect product for 10 patients. This is one of 10 reports.   A female patient of unspecified age received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on 30Apr2021 as dose 2, single for covid-19 immunization. The patient's medical history and concomitant medications were not reported. The patient previously received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number was not reported), via an unspecified route on an unspecified date as dose 1, single for COVID-19 immunization. On an unspecified date, the patient experienced low estrogen, cannot sleep, cannot focus, depressed, anxiety and cannot concentrate. The patient was tested and test proved that she had low estrogen (values not reported). The events were non-serious. The patient underwent lab tests and procedures which included blood oestrogen: low on an unspecified date. The outcome of the events was unknown. No follow-up attempts are needed; Information about lot/batch number cannot be obtained. Sender's Comments: Linked Report(s) : -PFIZER_INC-202101533632.
Local reaction: erythema, heat, slight swelling for about 3 1/2 inch radius on Left upper arm where vaccine was administered on 9/27.  Onset of symptoms 24 hours post vaccination.  This was pneumovaccine # 1.   No shortness of breath or fever.  Allegra 180 mg po daily for 5 days and topical benadryl  2 times a day for 5 days.  Will follow up in office in 2 days.  If any breathing difficulties call 911.  Husband present and understands.  Patient has high chronic anxiety and white coat syndrome with poor retention of information.
(L) thigh has 2.5 X 2.5 cm indurated erythematous area @ VARIVAX site.
Patient experience hypoglycemic event immediately after vaccine injection.  Patient was able to self administer glucose to improved FSBS.  Patient also showed a erythema/rash at manubrium base of neck. Diaphoresis.   Per pt: "lightheadness", "foggy."  Pt self administered glucose diaphoresis diminished.  Pt stopped insulin pump and FSBS improved to (130s-160s),  from 50s.
About 3 hours in (2/2), upper arm hurt at injection site. By 11 pm on 2/2, pain was very bad. Took usual Atenolol at bedtime; also took 1 Tylenol at bedtime for the pain, which didn't provide any relief. Slept poorly. Around 4 am I had bone-crushing pain throughout my body, plus even worse pain from the tips of my fingers of my left hand through my torso. Was afraid I was having heart problems from the vaccine. By morning, temperature was 99.7 and resting pulse was 99. Temperature increased to 100.7 and stayed between 100.3 and 100.9 all day. Pulse stayed between 95 and 99 all day. Took Atenolol and Tylenol again before bedtime 2/3. Woke up 2/4 with a headache but pulse had dropped to 68 and temperature was normal. Arm still hurts but not as badly and mostly between elbow and shoulder and still achy all over. (I had a similar increase in pulse and temperature with the first two doses. Arm pain was more isolated.)
No additional adverse events reported; VARlVAX that was administered after improperly stored.; This spontaneous report was received from a medical assistant and refers to a 12-month-old patient of unknown gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided.  On an unknown date, the varicella virus vaccine live (oka/merck) (VARIVAX) lot # T027303, expiration date 12-AUG-2022, experienced the temperature excursion of (6 degrees Fahrenheit (F) to 14 F) (8.5 F) for 0 hours 18 minutes and 0 seconds; 6 F to 14 F (11.9 F) for 1 hour 0 minutes. Cumulative timeframe: 1 hour and 18 minutes. On 22-SEP-2021, the patient was vaccinated with an improperly stored dose of varicella virus vaccine live (oka/merck) (VARIVAX) 0.5 ml, lot # T032317 (formulation, concentration, dose number, route of administration and anatomical location were not reported) for prophylaxis (product storage error). There were no previous excursions reported. No additional adverse event was reported (No adverse event).
Side effects were arm pain, hand pain, chest pain, shoulder blade pain in addition to pain at injection site. Injection was given on Sunday, 1/29/12 and pain lasted until Thursday, Feb. 2nd, 2012.
Patient Presented to Pharmacy with mom to receive vaccines. After carefully evaluating patient's vaccine history, recommendations' were made for patient to receive the above vaccine. patient seemed very nervous but tried to put her mind at ease by discussing the weather, and her summer plans. The first vaccine was given. Waited for about 5 minutes to make sure patient was okay before proceeding to the next one. Patient said she was ok, so decision was made to give the second vaccine. A couple of minutes after the second vaccine, patient reported of feeling dizzy and cold.  Since this was a typical sign of syncope, I asked mom to help me lay patient on the ground. Patient did not show any signs of difficulty breathing or a true allergic reaction. However proper action plan was put in place should this happen. After 10  minutes patient said she felt fine, mom and I helped her sit back up in a chair and they were asked to wait in the pharmacy for about 20minutes while constantly checking on her. After 20minutes they decided to go ahead and leave. Patient was encouraged to seek medical help and contact us should and anything else result. Follow up call was made to patient and mom on 05/31/2019, Patient mom said patient was ok and was doing better after she ate. Another follow up call was made on 06/02/2019  and again patient said she was well.
Low-grade temperature, nauseated and fatigued. This also happened with the last IZ, however, states the symptoms were worse this time.
3 days post vax pt devel rash on palms & fingers on both hands; high fever (2mos) rash 6wks)-swollen elbows, knuckles knees, chronic fatigue, fainting w/loss of consciousness for 20mins, disoriented, 6 fainting episodes
The rash started about 2 yrs ago, and progressed and progressed. It's getting worse and disfiguring.; sister in law did have covid after the shot; A few weeks after the shot developed a rash on chest neck, and side of face; This spontaneous case was reported by a patient family member or friend and describes the occurrence of COVID-19 (sister in law did have covid after the shot), RASH ERYTHEMATOUS (A few weeks after the shot developed a rash on chest neck, and side of face) and RASH (The rash started about 2 yrs ago, and progressed and progressed. It's getting worse and disfiguring.) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     It was unknown if patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine.     In 2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, the patient experienced COVID-19 (sister in law did have covid after the shot) and RASH ERYTHEMATOUS (A few weeks after the shot developed a rash on chest neck, and side of face). On an unknown date, the patient experienced RASH (The rash started about 2 yrs ago, and progressed and progressed. It's getting worse and disfiguring.). At the time of the report, COVID-19 (sister in law did have covid after the shot) and RASH ERYTHEMATOUS (A few weeks after the shot developed a rash on chest neck, and side of face) had not resolved and RASH (The rash started about 2 yrs ago, and progressed and progressed. It's getting worse and disfiguring.) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Dosage text for suspect product was reported as unknown.  Concomitant drugs were not reported.  It was reported that after a few weeks of vaccination patient had rash which was red and raw looking and would not go out in public. Patient saw a dermatologist and took several medications, but nothing worked. The doctor wanted to put patient on another medication, but patient was unwilling to take it.
Reporting due to ?COVID arm? . arm is still warm to touch.  Has continued to spread since injection. Marked with pen on 2/13 because larger than 2/12. Now 2/14, redness exceeds markings of 2/13.
It started with a bit of a weird headache about 3 minutes after the shot. Then about 7 minutes after I started having a weird tingly itchy feeling around my mouth and left check.  Shortly after that, I had a weird itchy, tingling sensation in my throat. One of the pharmacy gentlemen administering shots gave me Benadryl immediately when I shared it with them. I waited an additional 10 minutes after the initial 20 minutes. The itching around my neck lasted for about 2.5 hours. I was fine, but today (the next day) I've been very itchy around my ears, eyes, neck, chest, and upper back. I did send an email message to my doctor about this as well.  I happened on this, as I was looking at the CDC site.
Vertigo; nausea; This spontaneous case was reported by a patient and describes the occurrence of VERTIGO (Vertigo) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 002F21A, 039K20A and 029A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 08-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 17-Aug-2021, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VERTIGO (Vertigo) (seriousness criterion hospitalization) and NAUSEA (nausea). The patient was hospitalized for 1 day due to VERTIGO. The patient was treated with MECLIZINE [MECLOZINE] for Nausea, at an unspecified dose and frequency. At the time of the report, VERTIGO (Vertigo) had not resolved and NAUSEA (nausea) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Computerised tomogram: negative (Negative) Negative. On an unknown date, Ear, nose and throat examination: negative (Negative) Negative. On an unknown date, Electrocardiogram: negative (Negative) Negative. On an unknown date, Magnetic resonance imaging: negative (Negative) Negative.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   On 08 Feb 2021, the patient got the first dose of Moderna COVID-19 vaccine (lot 039K20A) and second dose (lot 029A21A) was administered on 08 Mar2021. On 17 Aug 2021, the patient had the Moderna booster. Then she developed vertigo suddenly. It put her in the hospital for a day and put her on MECLIZINE for nausea. She was been to her internist, ENT, and audiologist. She had 3 hours of audiology testing, EKG, MRI, CT scan, and ENT full examination. All the tests were negative. It was considered as a side effect of the vaccine.  No concomitant medications were reported.; Sender's Comments: This case concerns a 77-year-old, female patient, with no relevant medical history, who experienced the serious, unexpected event of vertigo. The patient had vertigo after third dose of mRNA 1273 vaccine which required the patient to be hospitalized for 1 day. The patient underwent audiology testing, EKG, MRI, CT scan and full ENT examination which was all negative. Patient was given meclizine for nausea. The rechallenge is not applicable as patient received treatment for the events. The events were considered related to the product per the reporter's assessment. The benefit-risk relationship of mRNA 1273 vaccine is not affected by this report.
Red, intensely  itchy rash on both hands (predominately around knuckles but some between fingers, tops of hands  and on palms), both elbows (but most extreme on left elbow) and on soles of feet. The rash developed roughly 58 hours after vaccine.  Used cortisone topically and took Benadryl orally.  Symptoms subsided after 2 days.
onset of chills w/body aches 24FEB; t100.8-cervical nodes swollen & sore; rash appeared 26FEB; dx by MD 27FEb;
Was sick with my 2 vaccines; This spontaneous case was reported by a pharmacist and describes the occurrence of ILLNESS (Was sick with my 2 vaccines) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ILLNESS (Was sick with my 2 vaccines). At the time of the report, ILLNESS (Was sick with my 2 vaccines) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  No treatment medications were reported.   This case was linked to MOD-2022-448499 (Patient Link).
A 35-year-old female patient experienced an alteration of vision after receiving her first pre-exposure dose of RabAvert on 17 Sep 03. The patient's medical history included anxiety with injection and allergies to sulfa and codeine. Concomitant medication included Lexapro.   After receiving her first injection the patient experienced blurry vision in her left eye, lasting about 30 minutes. The event resolved. Later that day she experienced blurry vision in her right eye also lasting approximately 30 minutes. The patient has since recovered and has not had a repeat of these events. The patient reported these symptoms the nurse just prior to receiving a second dose of RabAvert. The second dose had not been given at the time of this report.   The nurse assessed the event as possibly related to RabAvert.
After my second vaccine I did have flu symptoms headache bodyaches etc. , I didn?t feel well for maybe three days . Whats is worse is that I?m experiencing a great deal of hair loss,! I?m literally having to spray my scalp with a root touchup to hide the hair loss! I spoke with a representative of a large hair care manufacture she said  is experiencing hair loss after actually having COVID-19 and many of her friends that are experiencing the same thing.  I just looked up hair loss with the Pfizer COVID-19 vaccine and see several reports that they are experiencing the same thing that I am.  Unfortunately no one has seen any improvement and everyone is very concerned that this is going to continue including myself.
Hep A site, fever 104, red, swollen injection site- less than 24 hrs. Patient irritable + crying frequently.  Influenza site:  Normal.
My son was complaining of a sore arm and as of last Monday he was diagnosed with a sinus infection, and he missed school for a few days. I gave him the medication the doctor prescribed which was amoxicillin.
pt had a fatal sids on 25DEC92 @ 840AM; this is being reported only because of the time sequence to vax administration 22DEC92;
Pt developed generalized rash the night after she received HPV #3 and Men B #1.